Terkko Navigator / Journal of Child and Adolescent Psychopharmacology

From the Editor-in-Chief's Desk

Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6–12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study

From the Editor-in-Chief's Desk

Management of Acute Agitation and Aggression in Children and Adolescents with Pro Re Nata Oral Immediate Release Antipsychotics in the Pediatric Emergency Department

From the Editor-in-Chief's Desk

From the Editor-in-Chief's Desk

Implementation of Home-Based Telemental Health in a Large Child Psychiatry Department During the COVID-19 Crisis

Effects of Extended-Release Methylphenidate Treatment on Cognitive Task Performance in Children with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder

Post hoc Responder and Remission Analyses from Two Studies of SHP465 Mixed Amphetamine Salts Extended-Release Among Adults with Attention-Deficit/Hyperactivity Disorder

Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe

Epidemiology of Treatment for Preschoolers on Kentucky Medicaid Diagnosed with Attention-Deficit/Hyperactivity Disorder

Child and Parental Characteristics of Medication Use for Attention-Deficit/Hyperactivity Disorder

A Preliminary Study of the Effects of Treatment with Lithium Versus Quetiapine on Attention of Adolescents with Bipolar Disorder

Acute Dystonic Reaction to Aripiprazole in an Adolescent Boy

Pediatric Guanfacine Toxicity with Severely Elevated Plasma Concentration

Temporal Discounting Impulsivity and Its Association with Conduct Disorder and Irritability

Use of Tic-Suppressing Medication and Other Psychotropic Drugs in Children and Adolescents with Newly Diagnosed Tic Disorders in Denmark

Psychopharmacology in the Pediatric Oncology and Bone Marrow Transplant Units: Antipsychotic Medications Palliate Symptoms in Children with Cancer

CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders

Factor Structure of the Aberrant Behavior Checklist in Individuals with Fragile X Syndrome: Clarifications and Future Guidance

Role of Vitamin E in Olanzapine-Induced Hepatotoxicity

Greater Dynamic and Lower Static Functional Brain Connectivity Prospectively Predict Placebo Response in Pediatric Generalized Anxiety Disorder

Severe Psychotic Symptoms in Youth with PANS/PANDAS: Case-Series

Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study

Male-Specific Metabolic Considerations Concerning the Prescription of Second-Generation Antipsychotics to Adolescents

Use of Antipsychotics: The Experiences, Views, and Monitoring Practices of Child and Adolescent Psychiatrists in Turkey

Pediatric Acute-Onset Neuropsychiatric Syndrome: A Data Mining Approach to a Very Specific Constellation of Clinical Variables

Re:“Amantadine for Treatment of Disruptive Mood Dysregulation Disorder Symptoms” by Rice T et al. (J Child Adolesc Psychopharmacol 29:642–646, 2019)

Lurasidone in Children and Adolescents with Bipolar Depression Presenting with Mixed (Subsyndromal Hypomanic) Features: Post Hoc Analysis of a Randomized Placebo-Controlled Trial

From the Editor-in-Chief's Desk

The Association with Quantitative Response to Attention-Deficit/Hyperactivity Disorder Medication of the Previously Identified Neurodevelopmental Network Genes

A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up

Frequency and Correlates of Acute Dystonic Reactions After Antipsychotic Initiation in 441 Children and Adolescents

The Importance of Second-Generation Antipsychotic-Related Weight Gain and Adherence Barriers in Youth with Bipolar Disorders: Patient, Parent, and Provider Perspectives

Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part III—Treatment and Prevention of Infections

The Effects of Prior Authorization Policies on Medicaid-Enrolled Children's Use of Antipsychotic Medications: Evidence from Two Mid-Atlantic States